Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association. (PubMed, J Clin Lipidol) - Feb 26, 2026 - "A stepwise approach to optimal therapy is outlined, beginning with lifestyle interventions and pharmacotherapy with maximally tolerated statins and ezetimibe. This update incorporates newer agents, including proprotein convertase subtilisin/kexin type 9 inhibitors and bempedoic acid. Additional therapies, such as lomitapide and evinacumab for homozygous FH and lipoprotein apheresis for heterozygous and homozygous FH, are discussed. Further topics include cardiovascular imaging for risk stratification, management in specific populations and circumstances, such as planning for and during pregnancy and in pediatrics, and recognition of health disparities. This guidance equips clinicians with evidence-based strategies to improve the identification and care of patients with FH, ultimately reducing the high morbidity and mortality associated with this condition."
Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • Pediatrics
|
|
Allison Jamison; Amit Khera; Ana Morales; Anandita Agarwala; Anne C Goldberg; Bruce A Warden; Daniel E Soffer; Dinesh Kalra; Iftikhar J Kullo; Joseph J Saseen; Joshua W Knowles; Lauren Williams; Lisa Hudgins; Marina Cuchel; Mark A Rothstein; P Barton Duell; Robert A Hegele; William S Weintraub; Zahid Ahmad
|